← Back to patent-cliff list
卡格列净
Tier C — Watch / tradeCanagliflozin Hemihydrate
田边三菱制药株式会社
Originator
2013
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：SGLT2
Brand：Invokana、Canaglu
Indications (approved)：二型糖尿病、糖尿病肾病
Regional status
US
批准上市
2013-03-29
EU
批准上市
2013-11-15
China
批准上市
2017-09-29
Japan
批准上市
2014-07-04
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Canagliflozin Hemihydrate?
Approved indications include: 二型糖尿病, 糖尿病肾病.
When does the Canagliflozin Hemihydrate patent expire?
No public expiry year is available for Canagliflozin Hemihydrate yet; this page updates once verified.
How do I get a quote for Canagliflozin Hemihydrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25